United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - flucloxacillin magnesium; ampicillin trihydrate - oral suspension - 25mg/1ml ; 25mg/1ml

Ireland - English - HPRA (Health Products Regulatory Authority)

novartis ireland limited - oxcarbazepine - oral suspension - 60 milligram(s)/millilitre - carboxamide derivatives; oxcarbazepine

Malta - English - Medicines Authority

novartis pharmaceuticals uk limited frimley business park, frimley camberley, surrey gu16 7sr, united kingdom - oxcarbazepine - oral suspension - oxcarbazepine 60 mg/ml - antiepileptics

Singapore - English - HSA (Health Sciences Authority)

pfizer private limited - fluconazole - suspension - 200 mg/5 ml - fluconazole 200 mg/5 ml

Singapore - English - HSA (Health Sciences Authority)

pfizer private limited - fluconazole - suspension - 50 mg/5 ml - fluconazole 50 mg/5 ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

genus pharmaceuticals ltd - fluconazole - oral suspension - 10mg/1ml

Singapore - English - HSA (Health Sciences Authority)

msd pharma (singapore) pte. ltd. - posaconazole - suspension - 40mg/ml - posaconazole 40mg/ml

Singapore - English - HSA (Health Sciences Authority)

pfizer private limited - voriconazole - powder, for suspension - 40mg/ml - voriconazole 40mg/ml

Ireland - English - HPRA (Health Products Regulatory Authority)

novartis pharmaceuticals uk ltd - oxcarbazepine - oral suspension - 60 mg/ml - antiepileptics

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - ciclosporin, quantity: 100 mg/ml - oral liquid, solution - excipient ingredients: dl-alpha-tocopherol; ethanol; corn glycerides; propylene glycol; peg-40 hydrogenated castor oil - as an immunosuppressive agent for the prevention of graft rejection following kidney, liver and heart allogeneic transplantation. for induction and/or maintenance of remission in the nephrotic syndrome. cyclosporin is not a first-line agent. its use should be restricted to occasions when steroids and cystostatic drugs have failed, or are not tolerated, or are considered inappropriate, and when renal function is unimpaired (see warnings). for the treatment of severe, active rheumatoid arthritis in patients for whom classical slow-acting antirheumatic agents (including methotrexate) are inappropriate or ineffective. in patients with severe psoriasis in whom conventional therapy is ineffective or inappropriate and the disease has caused a significant interference with quality of life. additional indication from 11 june 1997: for the treatment of severe atopic dermatitis when other treatment is ineffective or inappropriate.